37 research outputs found

    ์„ค์น˜๋ฅ˜์˜ [18F]Mefway์—์„œ ๋‡Œ ์„ญ์ทจ์— ๊ธฐ์—ฌํ•˜๋Š” P-glycoprotein์˜ ํšจ๊ณผ

    Get PDF
    Dept. of Medicine/๋ฐ•์‚ฌI. INTRODUCTION Efflux transporters in brain capillary endothelial cells impede xenobiotics, including therapeutic drugs and PET radioligands. Of these, P-gp (P-glycoprotein) and Bcrp (Breast cancer resistance protein) are prominent efflux pumps. P-gp is colocalized with Bcrp on the luminal membranes of brain capillary endothelial cells, and they have partly overlapping substrate specificities that include a wide range of compounds. Thus, to investigate the effects of P-gp, it is required to evaluate the impact of Bcrp. The aim of this study was to determine whether the brain uptake of [18F]Mefway is influenced by the action of P-gp and Bcrp in rodents. II. MATERIALS AND METHODS To effectively suppress in vivo defluorination, fluconazole (OneFlu, JW Pharmaceutial, Seoul, Korea) was used. [18F]Mefway was applied to the pharmacological inhibition rats and genetically disrupted mice. In rats, blocking of P-gp activity was performed by tariquidar (TQD). For the pharmacological inhibition experiments male Sprague-Dawley (n = 3 for each group) rats were used. For genetic disruption, male Mdr1a/b(-/-), Bcrp1(-/-), Mdr1a/b(-/-)Bcrp1(-/-), and wild-type (WT) mice were used (n = 4 for each group). III. RESULTS Pretreatment of TQD results in 160% higher hippocampal uptake compared with control rats. In genetically disrupted mice, a maximal brain uptake value of 3.2 SUV in the triple knockout mice (Mdr1a/b(-/-)Bcrp1(-/-) was comparable to that of the double knockout mice (Mdr1a/b(-/-)) and two-fold those of the wild type and Bcrp1(-/-) knockout mice. The differences of binding values were statistically insignificant between control and experimental groups. The brain-to-plasma ratios for triple knockout mice were also 2-5 times higher than those for other groups. IV. CONCLUSION In PET, chemical knockout P-gp disruption induced considerable increase of brain uptake of [18F]Mefway compared with control group or wild type. This result was substantiated by ex vivo experiments showing high brain-to-plasma ratios for P-gp disrupted mice. In conclusion, [18F]Mefway is modulated by P-gp, and not by Bcrp in rodents. I. ๋ชฉ์  ๋‡Œ ๋ชจ์„ธํ˜ˆ๊ด€ ๋‚ดํ”ผ ์„ธํฌ์—์„œ ์œ ์ถœ ์šด๋ฐ˜์ž๋“ค์€ ์น˜๋ฃŒ ์•ฝ๋ฌผ๋“ค๊ณผ PET ๋ฐฉ์‚ฌ์„ฑ ๋ฆฌ๊ฐ„๋“œ๋“ค์„ ํฌํ•จํ•œ ์ƒ์ฒด์ด๋ฌผ์งˆ๋“ค์„ ๋ฐฉํ•ดํ•œ๋‹ค. ์ด๋“ค ์ค‘์—์„œ P-glycoprotein (P-gp)์™€ breast cancer resistance protein (Bcrp)๋Š” ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์œ ์ถœ ์šด๋ฐ˜์ž๋“ค์ด๋‹ค. P-gp๋Š” ๋‡Œ ๋ชจ์„ธํ˜ˆ๊ด€ ๋‚ดํ”ผ ์„ธํฌ์˜ ๊ด€๊ฐ•๋‚ด๋ง‰์— Bcrp์™€ ํ•จ๊ป˜ ๋ฐœํ˜„์ด ๋˜์–ด ์žˆ์œผ๋ฉฐ ์ผ๋ถ€ ๊ธฐ์งˆ ํŠน์ด์„ฑ์„ ๊ณต์œ ํ•˜๊ณ  ์žˆ๋‹ค. ๋”ฐ๋ผ์„œ P-gp์˜ ํšจ๊ณผ๋ฅผ ์•Œ์•„๋ณด๊ธฐ ์œ„ํ•ด์„œ๋Š” Bcrp์˜ ํšจ๊ณผ๋ฅผ ์•Œ์•„๋ณผ ํ•„์š”์„ฑ์ด ์žˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ์˜ ๋ชฉ์ ์€ ์„ค์น˜๋ฅ˜์˜ [18F]Mefway์—์„œ P-glycoprotein (P-gp)์™€ breast cancer resistance protein (Bcrp)์˜ ๋‡Œ์„ญ์ทจ์— ๊ด€๋ จ๋œ ํšจ๊ณผ๋ฅผ ์•Œ์•„๋ณด๊ณ ์ž ํ•˜์˜€๋‹ค. II. ๋Œ€์ƒ ๋ฐ ๋ฐฉ๋ฒ• ํƒˆ๋ถˆ์†Œํ™”๋ฅผ ํšจ๊ณผ์ ์œผ๋กœ ์–ต์ œ์‹œํ‚ค๊ธฐ ์œ„ํ•˜์—ฌ fluconazole (OneFlu, JW Pharmaceutial, ์„œ์šธ, ๋Œ€ํ•œ๋ฏผ๊ตญ)๋ฅผ ์‚ฌ์šฉํ•˜์˜€๋‹ค. [18F]Mefway๋ฅผ ์•ฝ๋ฌผํ•™์ ์œผ๋กœ ์–ต์ œ์‹œํ‚จ ์ฅ์™€ ์œ ์ „์ ์œผ๋กœ ๋ณ€ํ˜•์‹œํ‚จ ์ƒ์ฅ์—๊ฒŒ ์ ์šฉ์„ ํ•˜์˜€๋‹ค. ์ฅ์—์„œ๋Š” tariquidar(TQD)๋ฅผ ์ด์šฉํ•˜์—ฌ P-gp ๊ธฐ๋Šฅ์„ ์–ต์ œ ์‹œ์ผฐ๋‹ค. ์•ฝ๋ฌผํ•™์ ์œผ๋กœ ์–ต์ œ์‹œํ‚ค๋Š” ์‹คํ—˜์„ ์œ„ํ•ด์„œ๋Š” ์ˆ˜์ปท Sprague-Dawley (๊ฐ ๊ทธ๋ฃน ๋‹น ์„ธ ๋งˆ๋ฆฌ) ์ฅ๋ฅผ ์‚ฌ์šฉํ•˜์˜€๋‹ค. ์œ ์ „์  ๋ณ€ํ˜•์„ ์œ„ํ•˜์—ฌ์„œ๋Š” ์ˆ˜์ปท Mdr1a/b(-/-), Bcrp1(-/-), Mdr1a/b(-/-)Bcrp1(-/-), ๊ทธ๋ฆฌ๊ณ  ๋Œ€์กฐ๊ตฐ ์ƒ์ฅ๊ฐ€ ์‚ฌ์šฉ๋˜์—ˆ๋‹ค (๊ฐ ๊ทธ๋ฃน ๋‹น ๋„ค ๋งˆ๋ฆฌ). III. ๊ฒฐ๊ณผ TQD๋ฅผ ์ „์ฒ˜์น˜ํ•จ์œผ๋กœ์จ ๋Œ€์กฐ๊ตฐ ์ฅ์™€ ๋น„๊ต ์‹œ ํ•ด๋งˆ์˜ ๋‡Œ ์„ญ์ทจ๊ฐ€ 160% ์ฆ๊ฐ€๋˜์—ˆ๋‹ค. ์œ ์ „์ ์œผ๋กœ ๋ณ€ํ˜•๋œ ์ƒ์ฅ์—์„œ, ์ตœ๋Œ€ ๋‡Œ ์„ญ์ทจ๊ฐ€ 3.2 SUV์ธ ์‚ผ์ค‘ ์œ ์ „์ž ๊ฒฐ์† ์ƒ์ฅ (tKO, Mdr1a/b(-/-)Bcrp1(-/-) ์™€ ๋น„๊ต ์‹œ ์ด์ค‘ ์œ ์ „์ž ๊ฒฐ์† ์ƒ์ฅ (dKO, Mdr1a/b(-/-)) ์™€ ์ตœ๋Œ€ ๋‡Œ ์„ญ์ทจ๊ฐ€ ๋น„์Šทํ•˜์˜€์œผ๋ฉฐ ๋Œ€์กฐ ๊ตฐ๊ณผ Bcrp1(-/-) ์œ ์ „์ž ๊ฒฐ์† ์ƒ์ฅ์™€ ๋น„๊ต ์‹œ ๋‘ ๋ฐฐ ๋†’์€ ์ตœ๋Œ€ ๋‡Œ ์„ญ์ทจ๋ฅผ ๋ณด์˜€๋‹ค. ๋Œ€์กฐ ๊ตฐ๊ณผ ์‹คํ—˜ ๊ตฐ๊ฐ„์˜ ๊ฒฐํ•ฉ ๊ฐ€์น˜์˜ ์ฐจ์ด๋Š” ํ†ต๊ณ„์ ์œผ๋กœ ์˜๋ฏธ๊ฐ€ ์—†๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. [18F]Mefway ๋†๋„์˜ ๋‡Œ์™€ ํ˜ˆ์žฅ๊ฐ„ ๋น„์œจ์€ ๋‹ค๋ฅธ ๊ทธ๋ฃน๊ณผ ๋น„๊ต ์‹œ ์‚ผ์ค‘ ์œ ์ „์ž ๊ฒฐ์† ์ƒ์ฅ์—์„œ 2.5๋ฐฐ ๋†’์€ ๊ฒƒ์œผ๋กœ ํ™•์ธ๋˜์—ˆ๋‹ค. IV. ๊ฒฐ๋ก  PET์—์„œ ํ™”ํ•™์ ์œผ๋กœ P-gp ๊ฒฐ์—ฌ๋œ ๊ฒฝ์šฐ ๋Œ€์กฐ๊ตฐ๊ณผ ๋น„๊ต์‹œ [18F]Mefway์˜ ๋‡Œ์—์„œ ์„ญ์ทจ๋„๊ฐ€ ๋งค์šฐ ๋งŽ์ด ์ฆ๊ฐ€๋˜์—ˆ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋Š” P-gp ๊ฒฐ์† ์ƒ์ฅ์—์„œ๋„ ๋†’์€ ๋‡Œ-ํ˜ˆ์žฅ๊ฐ„ ๋น„์œจ์„ ๋ณด์ธ ์‹คํ—˜ ๊ฒฐ๊ณผ์—์„œ๋„ ์ž…์ฆ๋˜์—ˆ๋‹ค. ๊ฒฐ๋ก ์ ์œผ๋กœ [18F]Mefway๋Š” ์„ค์น˜๋ฅ˜์—์„œ Bcrp๊ฐ€ ์•„๋‹Œ P-gp์— ์˜ํ•ด์„œ ์กฐ์ ˆ์ด ๋œ๋‹ค.ope

    Haemodynamic events and localised parenchymal changes following transcatheter arterial chemoembolisation for hepatic malignancy: interpretation of imaging findings.

    Get PDF
    Following transcatheter arterial chemoembolisation (TACE), the appearances on CT or MR images are largely related to the chemical and ischaemic insults to the portal tract. Understanding the mechanism of TACE-induced changes is essential for radiologists in order to determine the therapeutic effect as well as to distinguish these changes from recurrent tumours. This pictorial review illustrates the haemodynamic and substantial parenchymal changes related to TACE for hepatic malignancy.ope

    Value of the US BI-RADS final assessment following mastectomy: BI-RADS 4 and 5 lesions

    Get PDF
    BACKGROUND: Clinical examination is not entirely sufficient for evaluation of the postoperative site for follow-up of patients with mastectomy. A few studies have reported that postoperative follow-up US evaluation allows early detection and proper management of local tumor recurrence. PURPOSE: To evaluate the diagnostic performance of the American College of Radiology (ACR) ultrasonographic (US) Breast Imaging Reporting and Data System (BI-RADS) categories 4 and 5 breast lesions at the mastectomy site. MATERIAL AND METHODS: Our institutional review board approved this study and waived the need for informed consent. We retrospectively reviewed the consecutive post-mastectomy US exams for palpable and non-palpable lesions in the post-mastectomy chest wall that were categorized as BI-RADS 4 (subcategorized 4a, 4b, and 4c) or 5 between January 2007 and April 2010. The positive predictive value (PPV) for final assessment was evaluated. RESULTS: From 2681 post-mastectomy US examinations, we obtained a study population of 50 patients with 50 lesions (20 palpable, 30 non-palpable). There were nine (45%) malignancies among the palpable lesions and six (20%) malignancies among the non-palpable lesions. The palpability showed no significant correlation with malignancy in overall subcategorization (P >0.05). The PPVs of categories 4 and 5 were 14.3% for category 4a, 62.5% for category 4b, 100% for category 4c, and 100% for category 5. CONCLUSION: The ACR US BI-RADS categorization of 4a, 4b, 4c, and 5 for breast lesions at the mastectomy site is a feasible method for predicting local recurrence. All lesions should be managed according to US characteristics during evaluation of local recurrence at the mastectomy site, regardless of palpability.ope

    Initially non-diagnostic ultrasound-guided fine needle aspiration cytology of thyroid nodules: value and management.

    Get PDF
    BACKGROUND: Ultrasound (US)-guided fine needle aspiration cytology (FNAC) is an accurate, reliable, and simple method to identify a thyroid nodule as benign or malignant. However, non-diagnostic cytology results for thyroid nodules are a major limitation of US-guided FNAC. PURPOSE: To investigate the incidence of thyroid cancer among cases with non-diagnostic results on FNAC and to provide suggestions for the management of thyroid nodules that are initially non-diagnostic by FNAC according to ultrasonographic findings. MATERIAL AND METHODS: From July 2006 to December 2009, 10,317 thyroid nodules in 6684 consecutive patients underwent US-guided FNAC at our institute. Among these, 871 thyroid nodules (8.4%) were diagnosed as non-diagnostic on initial cytologic evaluation and 196 underwent a second or third FNAC. Twenty-seven thyroid nodules (18.9%) underwent surgery, while 116 thyroid nodules were cytologically confirmed as benign with no remarkable change on follow-up US were included. We retrospectively reviewed the US findings for a total of 143 thyroid nodules (123 benign nodules and 20 malignant nodules). The US features that we compared included composition, echogenicity, margin, calcifications, shape, and underlying echogenicity. RESULTS: In total, thyroid cancer was diagnosed in 20 nodules (14.0%). The size of the nodule was significantly associated with malignancy (P < 0.05). Most of the sonographically probable benign nodules were found to be benign (97.6%). Suspicious nodules on US were thyroid cancer in 43.2% of cases. Marked hypoechogenicity, microlobulated or irregular margin, microcalcifications, and taller-than-wide shape were significant US findings that correlated with malignancy (P < 0.05). The diagnostic performance of ultrasound for initially non-diagnostic thyroid nodules was as follows: sensitivity of 90.0%, specificity of 65.0%, positive predictive value of 29.5%, and negative predictive value of 97.6%. CONCLUSION: In terms of management of thyroid nodules with non-diagnostic FNAC cytology, US evaluation is a feasible and useful method for predicting malignancy.ope

    Hermann Cohen ์˜ Kant ํ•ด์„

    No full text
    Hermann Cohen์— ์˜ํ•˜๋ฉด Kant๋Š” ๊ทธ์˜ ํ•™์  ํ™œ๋™์˜ ์ดˆ๊ธฐ์— Newton์— ์˜ํ•ด ์›๋ฆฌ์˜ ์ฒด๊ณ„๋กœ ์ •์ดˆ๋œ ์ž์—ฐ๊ณผํ•™์„ ์•Œ๊ฒŒ ๋˜์—ˆ๋‹ค. ๊ทธ๋ฆฌ๊ณ  ์ž์—ฐ๊ณผํ•™์—์„œ ์ธ์‹์ผ๋ฐ˜์˜ ์ด์ƒ์„ ์ดํ•ดํ•˜๊ฒŒ ๋˜์—ˆ๋‹ค. ์ด๋Ÿฌํ•œ ์ด์ƒ์˜ ์‚ฌ์ƒ์•ˆ์—๋Š” ์ธ์‹์˜ ์ฒด๊ณ„์— ๋Œ€ํ•œ ์ด์ƒํ™”ํ•œ ๊ฒƒ์˜ ๊ด€๊ณ„๊ฐ€ ์žˆ๋‹ค. ์ด ๊ด€๊ณ„๋ฅผ Kant๋Š” ๋ฌผ๋ก  ๊ทธ ์™„์ „ํ•œ ์˜๋ฏธ๋กœ ํŒŒ์•…ํ•  ์ˆ˜๋Š” ์—†์—ˆ๋‹ค. ๊ทธ๊ฐ€ ๊ฐœ๋ณ„์  ์ž์—ฐ๊ณผํ•™์„ ํ†ตํ•ด์„œ ์ฒ ํ•™์  ๋ฌธ์ œ์ œ๊ธฐ์— ๋„๋‹ฌํ•œ ๊ฒƒ์ด ์•„๋‹Œ ํ•œ, ๊ทธ๋Ÿฌํ–ˆ๋‹ค. ์ด์™€ ๋ฐ˜๋Œ€๋กœ ์ผ๋‹จ ์ฒ ํ•™์  ์‹œ์ ์ด ํŒŒ์•…๋œ ํ›„์—, ์ด์ƒ์œผ๋กœ์„œ ์š”๊ตฌ๋˜๋Š” ์ธ์‹์˜ ์‚ฌ์‹ค์ด ํ•™์  ์ด์„ฑ์— ๊ด€๊ณ„๋˜๊ณ  ํ•™์  ์ด์„ฑ์— ๊ธฐ์ดˆ๋˜์—ˆ๋‹ค๋Š” ๋ฐฉ์‹์œผ๋กœ ์ด ๊ด€๊ณ„๊ฐ€ ์ด์ƒ์˜ ์‚ฌ์ƒ์—์„œ ํƒ€๋‹น์œผ๋กœ ๋‚˜์•„๊ฐ”๋‹ค. ์ด๋Ÿฌํ•œ ๊ด€๊ณ„์•ˆ์—์„œ ์ธ์‹์ผ๋ฐ˜์˜ ์ฒด๊ณ„์˜ ํ†ต์ผ์ด ์‚ฌ์œ ๋˜์—ˆ๋‹ค. Newton์˜ ๊ณผํ•™์ด ์ด๋Ÿฌํ•œ ๊ด€๊ณ„์•ˆ์—์„œ ๊ณ ์ •๋จ์œผ๋กœ์จ, ์ด Newton์˜ ๊ณผํ•™์„ ์ธ์‹์˜ ์ด์ƒ์œผ๋กœ์„œ ์š”๊ตฌํ•˜๊ณ , ๋‹ค๋ฅธ ๊ณผํ•™๋“ค์˜ ์ •์œ„๋ฅผ ์ด Newton์˜ ๊ณผํ•™์—์„œ ๊ณ ์ฐฐํ•˜๋Š” ๊ฒƒ์ด ์ด์ œ ์ฒ ํ•™์ ์œผ๋กœ ์ค‘์š”ํ•œ ์˜๋ฏธ๋ฅผ ๊ฐ€์กŒ์„ ๊ฒƒ์ด๋‹ค

    Heidegger ์˜ ์‹ค๋ฌผ์˜ ๋ฌธ์ œ

    No full text

    "Alois Riehl Kantinterpretation"

    No full text
    Naeh der Meinung A. Riehls ist die Frage der Vernunftkritik Kants eine Frage nach ler Erkenntnis. Jedoch erfordert sie zu ihrer Beantwortung keine vollstรคndige "'Theorie ler menschlichen Erkenntnis." Die Aufgabe ist beschrรคnkt auf die Erkenntnis a priori; das viele "Empirische und Sinnliche" bleibt auรŸer Betracht. Die fรผr die ganze Untersuchung maรŸgebliche Formulierung lautet: Wie sind synthetische Urteile apriori mรถglich? Und zwar zielt die Mรถglichkeitsfrage nicht auf die zu ermรถglichende Wirklichkeit, sondern auf die zu begrรผndende objektiye Gรผltigkeit solcher Urteile. Alois Riehl betont mehrfach, das Problem Kants sei ein Iediglich erkenntnistheoretisches Problelm. Auf die Erkenntnis gehe die kritische Frage, nicht auf die Existenz. Dennoch ist der Denker an der Seinsweise des Dinges an sich lebhaft interessiert. Das kรถnnte schon darum verstรคndlich scheinen, weil sich im kritischen System die Frage nach der Erkenntnis nicht von der nach der Gegenstรคndlichkeit trennen lรครŸt, und weil bei dieser der Ausblick auf das Ding-an-sich Problem nahe liegt. Tatsรคchlich reiรŸt Riehl aber Erkenntnis des Gegenstandes und Gegenstand der Erkenntnis in einer Weise auseinander, die diese Erklรคrung nicht zulรครŸt. Vielmehr ist hier an das Problem zudenken, in dessen Erรถrterung Riehl รผberhaupt zur kritischen Fragestellung gefรผhrt wird: An das der Mรถglichkeit der positiven Wissenschaften. Der Punkt, an dem Riehls Interpretation vรถllig versagt, ist demnach die Begrรผndung ler Erfahrungsgegenstรคdlichkeit, ihre Begrรผndung nรคmlich im streng kritishen Sinnc

    ๊ฐ‘์ƒ์„  ๊ฒฐ์ ˆ์˜ ์ดˆ๊ธฐ ๋น„์ง„๋‹จ์  ์ดˆ์ŒํŒŒ ์œ ๋„ํ•˜ ๋ฏธ์„ธ์นจํก์ธ์ˆ  ๊ฒฐ๊ณผ์˜ ํ‰๊ฐ€์™€ ์ฒ˜๋ฆฌ

    No full text
    Dept. of Medicine/์„์‚ฌ[ํ•œ๊ธ€] [์˜๋ฌธ]I.INTRODUCTIONThe management of patients with thyroid fine-needle aspiration biopsy (FNAB) specimens that are nondiagnostic cytologic results still remains problematic. Aims of this study were to investigate the incidence of thyroid cancer among the initially nondiagnostic cases of FNAB and to compare the final cytopathologic results between probably benign and suspicious nodules in ultrasonography (US) with suggesting the management of initially nondiagnostic thyroid nodules at FNABs.II.MATERIALS AND METHODSFrom July 2006 to December 2009, 10,317 thyroid nodules in 6,684 consecutive patients underwent US-guided FNAB. Among them, 871 thyroid nodules (8.4%) that were diagnosed as nondiagnostic at initial cytologic evaluation and 196 thyroid nodules underwent subsequent second or third FNAB. Twenty-seven thyroid nodules (18.9%) were underwent surgery and 116 thyroid nodules were considered as benign which were cytologically confirmed as benign and showed no remarkable change at follow-up US. US findings of total 143 thyroid nodules (123 benign nodules and 20 malignant nodules) in 138 patients (M: F = 20: 118; mean age, 50.5 years) were retrospectively reviewed. US features were including internal composition, echogenicity, margin, calcifications, shape and underlying echogenicity.III.RESULTSIn total, thyroid cancers were diagnosed in 20 nodules (14.0%, 19 papillary carcinomas and one minimally invasive Hurthle cell cancer). Lesion size varied from 3 to 40mm (mean, 10.4mm). Fourteen lesions were palpable and the others were incidentally found. The size of lesion was significantly associated with malignancy (P < 0.05). Only two sonographically probable benign nodules revealed malignancy (2.4%). Suspicious nodule on US showed thyroid cancer in 43.2%. Markedly hypoechogenicity, microlobulated or irregular margin, microcalcifications and taller-than-wide shape were significant US findings that correlated with malignancy (P < 0.05). Diagnostic performance of ultrasound of initially nondiagnostic thyroid nodules was calculated as follow: sensitivity 90.0%, specificity 65.0%, positive predictive value 29.5 %, and negative predictive value 97.6%.IV.DISCUSSION Malignancy rates of thyroid nodules which were showed non-diagnostic result in FNAB was 14.0% in our study. Considering the management of thyroid nodules with nondiagnostic FNAB cytology, the US evaluation is a feasible method and useful in predicting malignancy. V.CONCLUSIONAlthough nondiagnostic cytologic result at initial FNAB, repeat FNAB is needed for sonographically suspicious nodules, due to 14% of malignancy rates in nondiagnostic thyroid nodules. However, follow-up US is more recommended rather than repeat FNAB for sonographically probably benign nodules. Sonographic findings of thyroid nodules with nondiagnostic results at FNABs are useful method to plan the management.ope

    ๋ฅด๋„ค์ƒ์Šค ์‹œ๋Œ€์˜ ์ฒ ํ•™

    No full text
    Agrippa๋Š” ์‹  Platon ์ฃผ์˜์™€ ์œ ํƒœ๊ต์˜ Kabbala์˜ ์‹ ๋น„์„ค์„ ๊ฒฐํ•ฉํ•œ Reuchlin์˜ ์˜ํ–ฅ์„ ๋ฐ›์•˜๋‹ค. ๋˜ ์ค‘์„ธ์˜ ์ฒ ํ•™์ž์ด๋ฉฐ ์‹ ๋น„๋ก ์ž์ธ Raymundus Lullus์˜ ์˜ํ–ฅ์„ ๋ฐ›์•˜๋‹ค. Agrippa์— ์˜ํ•˜๋ฉด ์šฐ์ฃผ๋Š” ๋ชจ๋“  ๋ถ€๋ถ„์— ์žˆ์–ด์„œ ์ž‘์šฉ์˜ ํ†ต์ผ์ ์ธ ์—ฐ๊ด€์„ ๊ฐ€์ง„๋‹ค. ๊ทธ๋Š” ์šฐ์ฃผ๋ฅผ ์…‹์œผ๋กœ ๋‚˜๋ˆ„๋Š” ๊ณ ๋ž˜์˜์ƒ๊ฐ์„ ๋ฐ›์•„๋“ค์ด๊ณ  ์žˆ๋‹ค ์ฆ‰ 1) ์ง€์ƒ์„ธ๊ณ„(์ง€ ยท ์ˆ˜ ยท ๋ถˆ ยท ํ’์˜ ์„ธ๊ณ„) 2)์„ฑ ์ฆ‰ ์ฒœ์˜(himmlische Welt) 3) ์ฒœ์‚ฌ์˜ ์˜ˆ์ง€์  ์„ธ๊ณ„(intelligible welt) ๋˜๋Š” ๊ด€๋…์ ์ธ ์„ธ๊ณ„(ideelle Welt)๋กœ์จ, ์ด ์„ธ ์„ธ๊ณ„์—์„œ ์ž‘์šฉ์˜ ์›๋ฆฌ๋Š” ๋™์ผํ•˜๋‹ค. ํ˜„์‹ค์  ์ƒ๊ธฐํ˜„์ƒ์— ์‹ ์˜ ์˜์‚ฌ๊ฐ€ ๊ทธ๊ฒƒ์— ์นจ์ž…ํ•œ๋‹ค๋Š” ๊ฒƒ์€ ์ƒ๊ฐ๋˜์ง€ ์•Š๋Š”๋‹ค. ์ผ์ฒด์˜ ์‚ฌ๋ฌผ์ด๋‚˜ ํž˜์€, ํ•˜๋‚˜์˜ ์™„๊ฒฐ์ ์ธ ์„ธ๊ณ„ ์—ฐ๊ด€์„ ์ด๋ฃจ๊ณ  ์žˆ๋‹ค. ๋”ฐ๋ผ์„œ ์ธ๊ฐ„์€ ์ž๊ธฐ ๋‚ด๋ถ€์— ์‚ฌ๋ฌผ์˜ ํž˜๊ณผ ๊ฐ€๊นŒ์šด ๊ฒƒ์„ ์ž๊ฐํ•˜๋ฉด ํ• ์ˆ˜๋ก ์ ์  ๋” ์ž์—ฐ์— ์˜ํ–ฅ์„ ๋ฏธ์น  ์ˆ˜๊ฐ€ ์žˆ๋‹ค. ๊ทธ๋ฆฌํ•˜์—ฌ ์ธ๊ฐ„์€ ์ž์—ฐ์„ ์ง€๋ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค
    corecore